专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011160086A2 USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO TREAT ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM 审中-公开
标题翻译： B淋巴细胞刺激素蛋白拮抗剂用于治疗呼吸系统哮喘和其他过敏和炎症反应的条件
公开(公告)号：WO2011160086A2
公开(公告)日：2011-12-22
申请号：PCT/US2011/040985
申请日：2011-06-17
申请人： HUMAN GENOME SCIENCES, INC. , WASSERMAN, Heather , CARLSON, Timothy , MIGONE, Thi-sau , DEVALARAJA, Madhav
发明人： WASSERMAN, Heather , CARLSON, Timothy , MIGONE, Thi-sau , DEVALARAJA, Madhav
IPC分类号： A61K39/395 , A61K38/16 , A61K39/35 , A61P11/00 , A61P11/06
CPC分类号： C07K16/2875 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/622 , C07K2317/76
摘要： The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist.
摘要翻译：本发明涉及通过施用B淋巴细胞刺激物拮抗剂来预防，治疗和改善患者的肺或呼吸系统的哮喘，变应原诱发的呼吸症状和/或过敏或炎症状态的方法。此外，本发明提供了通过施用B淋巴细胞刺激物拮抗剂降低患有哮喘和/或肺或呼吸系统的过敏或炎症状况的患者中的总血清IgE水平的方法。本发明还提供了一种通过施用B淋巴细胞刺激物拮抗剂来治疗，预防或改善变应原诱发的气道高反应性或增加含粘液的细胞和/或患者气道上皮中的粘液积聚或产生的方法。

2. 发明申请

WO2007142667A3 TREATMENT OF PATIENTS WITH AUTOANTIBODY POSITIVE DISEASE 审中-公开
标题翻译：治疗患有自身免疫疾病的患者
公开(公告)号：WO2007142667A3
公开(公告)日：2008-12-18
申请号：PCT/US2006038756
申请日：2006-10-05
申请人： HUMAN GENOME SCIENCES INC , CHEVRIER MARC , FRIEMUTH WILLIAM , ZHONG ZHENSHAO , ODENHEIMER DANIEL , PERKINS MELISSA D
发明人： CHEVRIER MARC , FRIEMUTH WILLIAM , ZHONG ZHENSHAO , ODENHEIMER DANIEL , PERKINS MELISSA D
IPC分类号： C12P21/06 , A61K39/395 , A61K49/00 , C07H21/04 , C07K16/00
CPC分类号： C07K16/2875 , A61K38/185 , A61K2039/505 , A61K2039/507 , C07K14/70575 , C07K2317/56 , C07K2317/73
摘要： The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.
摘要翻译：本发明涉及用于治疗患有自身抗体阳性疾病的患者的方法和组合物。在一个具体实施方案中，本发明涉及一种治疗其血浆中抗dsDNA抗体的ANA效价为1:80或更高和/或大于或等于30IU / ml的患者的方法其包括施用治疗有效量的免疫调节剂，例如中枢神经氨酸α拮抗剂。另外提供了减少给予患者的皮质类固醇给药的频率和/或量的方法。在优选的实施方案中，患者具有系统性红斑狼疮。还提供了确定狼疮患者是否对医疗做出反应的方法。

3. 发明申请

WO2007146038A3 ALBUMIN FUSION PROTEINS 审中-公开
公开(公告)号：WO2007146038A3
公开(公告)日：2008-10-09
申请号：PCT/US2007013383
申请日：2007-06-07
申请人： HUMAN GENOME SCIENCES INC , ROSEN CRAIG A , BELL ADAM , LAFLEUR DAVID W , WOODS DOUGLAS B , FENG PING , SMITH RODGER G
发明人： ROSEN CRAIG A , BELL ADAM , LAFLEUR DAVID W , WOODS DOUGLAS B , FENG PING , SMITH RODGER G
IPC分类号： A61K38/26 , C07K14/605 , C07K14/76
CPC分类号： C12N9/96 , A61K38/00 , C07K14/765 , C07K2319/00 , C12N15/62
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

4. 发明申请

WO2007139873A2 HANDLING CONTAINER 审中-公开
标题翻译：处理容器
公开(公告)号：WO2007139873A2
公开(公告)日：2007-12-06
申请号：PCT/US2007012367
申请日：2007-05-24
申请人： HUMAN GENOME SCIENCES INC , COLANDENE JAMES , WU EUGENE , MEZGHEBE TESFU
发明人： COLANDENE JAMES , WU EUGENE , MEZGHEBE TESFU
IPC分类号： A61J1/06
CPC分类号： B65D81/127
摘要： The invention provides a handling container for shipping, storing, or handling a module containing a biopharmaceutical material. The handling container includes an outer shell having four side walls and a bottom end wall having an inner surface and defining an open compartment, a removable lid for closing the open compartment and one or more padding.
摘要翻译：本发明提供了用于运输，存储或处理包含生物药物材料的模块的处理容器。处理容器包括具有四个侧壁的外壳和具有内表面并限定开口隔室的底端壁，用于封闭开放室的可移除盖和一个或多个衬垫。

5. 发明申请

WO2005094524A3 CELL CULTURE APPARATUS AND METHODS 审中-公开
标题翻译：细胞培养装置及方法
公开(公告)号：WO2005094524A3
公开(公告)日：2006-09-28
申请号：PCT/US2005009843
申请日：2005-03-24
申请人： HUMAN GENOME SCIENCES INC , LIN WENGLONG ROY , BHATIA RAVINDER , KADARUSMAN JUDITH , MCLAUGHLIN JOHN
发明人： LIN WENGLONG ROY , BHATIA RAVINDER , KADARUSMAN JUDITH , MCLAUGHLIN JOHN
IPC分类号： C12N5/02 , C12N5/00 , C12N5/06 , C12N5/08
CPC分类号： C12N5/0018 , C12N2500/36
摘要： A method for culturing cells in a plastic culture vessel is provided. The method is suitable for use when it is desirable to have a small hydrophobic molecule present in the cell culture media at some point during incubation.
摘要翻译：提供了在塑料培养容器中培养细胞的方法。当期望在培养期间的某一点期望在细胞培养基中存在小的疏水性分子时，该方法适合使用。

6. 发明申请

WO2006081320A3 PHARMACEUTICAL FORMULATION 审中-公开
公开(公告)号：WO2006081320A3
公开(公告)日：2006-08-03
申请号：PCT/US2006/002696
申请日：2006-01-26
申请人： HUMAN GENOME SCIENCES, INC. , COLANDENE, James D. , SPITZNAGEL, Thomas M. , CREAGH, Alma , VRETTOS, John S. , MALDONADO, Linda M. , PERKINS, Melissa D. , GRILLO, Adeola O.
发明人： COLANDENE, James D. , SPITZNAGEL, Thomas M. , CREAGH, Alma , VRETTOS, John S. , MALDONADO, Linda M. , PERKINS, Melissa D. , GRILLO, Adeola O.
IPC分类号： A61K39/395 , C07K16/00 , C12P21/08
摘要： Lyophilization processes for a pharmaceutical formulation are provided in which the temperature of the product during the primary drying stage is above the glass transition temperature (Tg') of the formulation or above the glass transition temperature (Tg') and the collapse onset temperature (TO), but below the collapse temperature (Tc). A pharmaceutical formulation that includes a protein concentration of at least about 20 mg/mL is also provided. Additionally, a pharmaceutical formulation that includes little or no crystalline bulking agent and/or at least about 2% w/v disaccharide.

7. 发明申请

WO2006081320A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2006081320A2
公开(公告)日：2006-08-03
申请号：PCT/US2006002696
申请日：2006-01-26
申请人： HUMAN GENOME SCIENCES INC , COLANDENE JAMES D , SPITZNAGEL THOMAS M , CREAGH ALMA , VRETTOS JOHN S , MALDONADO LINDA M , PERKINS MELISSA D , GRILLO ADEOLA O
发明人： COLANDENE JAMES D , SPITZNAGEL THOMAS M , CREAGH ALMA , VRETTOS JOHN S , MALDONADO LINDA M , PERKINS MELISSA D , GRILLO ADEOLA O
IPC分类号： A61K38/17
CPC分类号： A61K9/19 , A61K9/0019 , A61K47/26 , A61K47/42
摘要： Lyophilization processes for a pharmaceutical formulation are provided in which the temperature of the product during the primary drying stage is above the glass transition temperature (Tg') of the formulation or above the glass transition temperature (Tg') and the collapse onset temperature (TO), but below the collapse temperature (Tc). A pharmaceutical formulation that includes a protein concentration of at least about 20 mg/mL is also provided. Additionally, a pharmaceutical formulation that includes little or no crystalline bulking agent and/or at least about 2% w/v disaccharide.
摘要翻译：提供了药物制剂的冻干方法，其中初级干燥阶段的产品的温度高于制剂的玻璃化转变温度（Tg'）或高于玻璃化转变温度（Tg'）和崩解开始温度（TO ），但低于塌陷温度（Tc）。还提供了包含至少约20mg / mL的蛋白质浓度的药物制剂。另外，包含很少或没有结晶填充剂和/或至少约2％w / v二糖的药物制剂。

8. 发明申请

WO2004042000A3 157 HUMAN SECRETED PROTEINS 审中-公开
标题翻译： 157人类分泌蛋白
公开(公告)号：WO2004042000A3
公开(公告)日：2005-10-06
申请号：PCT/US0315439
申请日：2003-05-16
申请人： HUMAN GENOME SCIENCES INC , ROSEN CRAIG A , RUBEN STEVEN M , OLSEN HENRIK , BAKER KEVIN P , FISCELLA MICHELE , WEI PING , BIRSE CHARLES E , KOMATSOULIS GEORGE , CHOI GIL H , MOORE PAUL A , GUPTA RAM , SHI YANGGU
发明人： ROSEN CRAIG A , RUBEN STEVEN M , OLSEN HENRIK , BAKER KEVIN P , FISCELLA MICHELE , WEI PING , BIRSE CHARLES E , KOMATSOULIS GEORGE , CHOI GIL H , MOORE PAUL A , GUPTA RAM , SHI YANGGU
IPC分类号： C07K14/47 , C07K1/00
CPC分类号： C07K14/47 , A61K38/00
摘要： The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
摘要翻译：本发明涉及人分泌多肽和编码所述多肽的分离的核酸分子，其可用于诊断和治疗与所述人分泌蛋白相关的疾病，病症和/或病症。结合这些多肽的抗体也包括在本发明中。本发明还包括载体，宿主细胞，以及用于产生所述多核苷酸，多肽和/或抗体的重组和合成方法。本发明还包括用于鉴定本发明的多核苷酸和多肽的激动剂和拮抗剂的筛选方法。本发明还包括用于抑制或增强本发明多肽的产生和功能的方法和组合物。

9. 发明申请

WO2005003296A3 ALBUMIN FUSION PROTEINS 审中-公开
标题翻译： ALBUMIN融合蛋白
公开(公告)号：WO2005003296A3
公开(公告)日：2005-04-21
申请号：PCT/US2004001369
申请日：2004-01-20
申请人： HUMAN GENOME SCIENCES INC , HASELTINE WILLIAM A , ROSEN CRAIG A
发明人： HASELTINE WILLIAM A , ROSEN CRAIG A
IPC分类号： A61K38/00 , A61K38/38 , A61K47/48 , C07H21/04 , C07K14/765 , C12N20060101 , C12P21/02 , C12P21/04
CPC分类号： A61K38/38 , A61K47/643 , C07K14/765 , C07K2319/31
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.
摘要翻译：本发明包括清蛋白融合蛋白。编码本发明的清蛋白融合蛋白的核酸分子也包括在本发明中，含有这些核酸的载体，用这些核酸载体转化的宿主细胞以及制备本发明的清蛋白融合蛋白并使用这些核酸的方法酸，载体和/或宿主细胞。此外，本发明涵盖包含清蛋白融合蛋白的药物组合物以及使用本发明的清蛋白融合蛋白治疗，预防或改善疾病，失调或病症的方法。

10. 发明申请

WO2004003144A3 ANTIBODIES THAT SPECIFICALLY BIND TO REG IV 审中-公开
标题翻译： IV特异性结合的抗体
公开(公告)号：WO2004003144A3
公开(公告)日：2004-06-10
申请号：PCT/US0319908
申请日：2003-06-26
申请人： HUMAN GENOME SCIENCES INC , ROSEN CRAIG A
发明人： ROSEN CRAIG A
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28 , C07K16/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/622
摘要： The present invention relates to antibodies and related molecules that specifically bind to Reg IV. Such antibodies have uses, for example, in the prevention and treatment of gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes. The invention also relates to nucleic acid molecules encoding anti-Reg IV antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to Reg IV.
摘要翻译：本发明涉及特异性结合Reg IV的抗体和相关分子。这些抗体例如用于预防和治疗胃肠道癌症，炎症性肠病和糖尿病。本发明还涉及编码抗Reg III抗体的核酸分子，含有这些核酸的载体和宿主细胞及其制备方法。本发明涉及用于预防，检测，诊断，治疗或改善疾病或病症，特别是胃肠道癌症，炎症性肠病和糖尿病的方法和组合物，所述方法和组合物包含给予动物，优选人类有效量的一种或更多的与Reg IV特异性结合的抗体或其片段或变体或相关分子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式